MG
SYRE icon

Michael Gelband’s Spyre Therapeutics SYRE Stock Holding History

Michael Gelband’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-87,065
Closed -$4.39M – 2053
2026
Q1 		$4.39M Buy
87,065
+49,194
+130% +$1.85M 0.03% 483
2025
Q4 		$1.24M Sell
37,871
-30,692
-45% -$802K 0.01% 914
2025
Q3 		$1.15M Sell
68,563
-14,414
-17% -$235K 0.01% 915
2025
Q2 		$1.24M Buy
82,977
+67,922
+451% +$1.01M 0.01% 899
2025
Q1 		$243K Sell
15,055
-1,636
-10% -$34K ﹤0.01% 1268
2024
Q4 		$389K Buy
16,691
+6,958
+71% +$204K ﹤0.01% 1216
2024
Q3 		$286K Buy
+9,733
New +$271K ﹤0.01% 1375
2024
Q2 		– Sell
-24,472
Closed -$928K – 1970
2024
Q1 		$928K Sell
24,472
-1,738
-7% -$50.4K 0.01% 971
2023
Q4 		$564K Buy
+26,210
New +$361K ﹤0.01% 1006
2023
Q2 		– Sell
-4,699
Closed -$34K – 2235
2023
Q1 		$34K Buy
4,699
+489
+12% +$5.37K ﹤0.01% 1675
2022
Q4 		$47K Buy
+4,210
New +$75.7K ﹤0.01% 1549
2019
Q2 		– Sell
-430
Closed -$87K – 1316
2019
Q1 		$87K Buy
+430
New +$89.6K 0.01% 618

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Michael Gelband's SYRE Position: Q2 2026 in Review

Michael Gelband sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 87,065 shares — an estimated $4.39M sold.

Michael Gelband first reported a position in SYRE in Q1 2019 and held it in 12 quarters. The position peaked at $4.39M in Q1 2026. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Michael Gelband reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 87,065 Spyre Therapeutics shares in Q2 2026, an estimated $4.39M.
  • Michael Gelband first reported a position in Spyre Therapeutics in Q1 2019 and held it in 12 quarters.
  • Michael Gelband's Spyre Therapeutics position peaked at $4.39M in Q1 2026.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.